|
Exosomal Drug Delivery
|
5R44CA221487-02
|
$1,000,000
|
SPENCER, WENDY
|
3P BIOTECHNOLOGIES, INC.
|
|
Targeted Therapy for Non Small Cell Lung Carcinoma: Human Phase 1 safety and dose escalation studies
|
5R44CA162629-03
|
$833,374
|
SERRERO, GINETTE
|
A AND G PHARMACEUTICAL, INC.
|
|
Core Support for Cancer Center
|
3P30CA013330-45S1
|
$3,646,138
|
GOLDMAN, ISRAEL
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Inhibition of Senescence to Increase Cancer Cell Death: A New Paradigm
|
5R01CA077263-19
|
$417,500
|
MCDAID, HAYLEY
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Crosstalk between the ER Stress Response and Mitochondrial Fatty Acid Oxidation in MYC-driven Breast Cancer
|
1R37CA228304-01
|
$362,569
|
CHEN, XI
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-12S1
|
$118,875
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-12S2
|
$249,997
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-12S3
|
$125,004
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
5P30CA125123-12
|
$3,203,119
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Identification of susceptibility to chemotherapy induced peripheral neuropathy using patient stem cell derived sensory neurons
|
5R03CA220219-02
|
$88,500
|
WOOLF, CLIFFORD
|
BOSTON CHILDREN'S HOSPITAL
|
|
TUMOR SPECIFIC DELIVERY OF VERTICILLIN A OVERCOMES EPIGENETIC SILENCING RESPONSIBLE FOR DRUG RESISTANCE
|
1R01CA227433-01
|
$608,862
|
GRINSTAFF, MARK
|
BOSTON UNIVERSITY (CHARLES RIVER CAMPUS)
|
|
Case Comprehensive Cancer Center Support Grant
|
2P30CA043703-28
|
$5,637,954
|
GERSON, STANTON
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Case Comprehensive Cancer Center Support Grant
|
3P30CA043703-28S1
|
$249,965
|
GERSON, STANTON
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Contribution of Gynecologic and Breast Cancer Biospecimens from African American women to HCMI
|
3P30CA043703-28S2
|
$48,000
|
GERSON, STANTON
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Targeting BET proteins in Triple Negative Breast Cancer
|
5R01CA206505-03
|
$366,913
|
KERI, RUTH
|
CASE WESTERN RESERVE UNIVERSITY
|
|
c-Abl-mediated Suppression of Breast Cancer Development and Metastasis
|
3R01CA177069-05S1
|
$75,000
|
SCHIEMANN, WILLIAM
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Nanoparticle-mediated treatment for bone metastasis
|
5R01CA206189-03
|
$312,562
|
LABHASETWAR, VINOD
|
CLEVELAND CLINIC LERNER COM-CWRU
|
|
Elucidating a novel molecular biomarker for castration-resistant prostate cancer
|
2R01CA172382-06
|
$380,000
|
SHARIFI, NIMA
|
CLEVELAND CLINIC LERNER COM-CWRU
|
|
Total Synthesis and Biosynthesis of Bioactive Substances
|
5R01CA070375-22
|
$256,101
|
WILLIAMS, ROBERT
|
COLORADO STATE UNIVERSITY
|
|
Therapeutic potential of enhanced mitochondrial biogenesis for paclitaxel-induced peripheral neuropathy
|
1R21CA226672-01
|
$208,800
|
HIRANO, MICHIO
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Dana-Farber/Harvard Cancer Center
|
3P30CA006516-53S1
|
$445,796
|
GLIMCHER, LAURIE
|
DANA-FARBER CANCER INST
|
|
Dana-Farber/Harvard Cancer Center
|
3P30CA006516-53S2
|
$59,495
|
GLIMCHER, LAURIE
|
DANA-FARBER CANCER INST
|
|
Dana-Farber/Harvard Cancer Center
|
3P30CA006516-53S3
|
$62,500
|
GLIMCHER, LAURIE
|
DANA-FARBER CANCER INST
|
|
Dana-Farber/Harvard Cancer Center
|
3P30CA006516-53S4
|
$149,528
|
GLIMCHER, LAURIE
|
DANA-FARBER CANCER INST
|
|
Dana-Farber/Harvard Cancer Center
|
3P30CA006516-53S5
|
$60,691
|
GLIMCHER, LAURIE
|
DANA-FARBER CANCER INST
|
|
Dana-Farber/Harvard Cancer Center
|
3P30CA006516-53S6
|
$228,108
|
GLIMCHER, LAURIE
|
DANA-FARBER CANCER INST
|
|
Dana-Farber/Harvard Cancer Center
|
3P30CA006516-53S7
|
$199,806
|
GLIMCHER, LAURIE
|
DANA-FARBER CANCER INST
|
|
Dana-Farber/Harvard Cancer Center
|
5P30CA006516-53
|
$11,504,298
|
GLIMCHER, LAURIE
|
DANA-FARBER CANCER INST
|
|
(PQ9) The role of Bclw (bcl2l2) in preventing chemotherapy induced neuropathy
|
5R01CA205255-03
|
$577,463
|
SEGAL, ROSALIND
|
DANA-FARBER CANCER INST
|
|
The mechanism of DNA damage and chromothripsis from chromosome segregation errors
|
5K08CA208008-03
|
$177,120
|
SPEKTOR, ALEXANDER
|
DANA-FARBER CANCER INST
|
|
Analysis of Blood Borne Markers in Hormone Sensitive Metastatic Prostate Cancer
|
5R01CA208254-03
|
$519,293
|
SWEENEY, CHRISTOPHER
|
DANA-FARBER CANCER INST
|
|
Winship Cancer Institute Cancer Center Support Grant
|
3P30CA138292-10S1
|
$72,918
|
CURRAN, WALTER
|
EMORY UNIVERSITY
|
|
Winship Cancer Institute Cancer Center Support Grant
|
3P30CA138292-10S2
|
$200,473
|
CURRAN, WALTER
|
EMORY UNIVERSITY
|
|
Winship Cancer Institute Cancer Center Support Grant
|
3P30CA138292-10S3
|
$234,000
|
CURRAN, WALTER
|
EMORY UNIVERSITY
|
|
Winship Cancer Institute Cancer Center Support Grant
|
5P30CA138292-10
|
$2,574,000
|
CURRAN, WALTER
|
EMORY UNIVERSITY
|
|
Enhancing immune therapy in pancreatic cancer by targeting IL-6
|
5R01CA208253-03
|
$321,742
|
LESINSKI, GREGORY
|
EMORY UNIVERSITY
|
|
Perfluorocarbon Nanodroplets for the Detection and Treatment of Nodal Metastases
|
5F30CA216939-02
|
$49,524
|
YARMOSKA, STEVEN
|
EMORY UNIVERSITY
|
|
Chlorotoxin as a Targeting Agent for Cancer Therapies
|
5R01CA135491-10
|
$396,000
|
OLSON, JAMES
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
Moffitt Cancer Center Support Grant
|
3P30CA076292-20S1
|
$60,000
|
SELLERS, THOMAS
|
H. LEE MOFFITT CANCER CTR & RES INST
|
|
Moffitt Cancer Center Support Grant
|
3P30CA076292-20S2
|
$86,294
|
SELLERS, THOMAS
|
H. LEE MOFFITT CANCER CTR & RES INST
|
|
Moffitt Cancer Center Support Grant
|
3P30CA076292-20S3
|
$185,151
|
SELLERS, THOMAS
|
H. LEE MOFFITT CANCER CTR & RES INST
|
|
Moffitt Cancer Center Support Grant
|
3P30CA076292-20S4
|
$75,701
|
SELLERS, THOMAS
|
H. LEE MOFFITT CANCER CTR & RES INST
|
|
Moffitt Cancer Center Support Grant
|
5P30CA076292-20
|
$2,990,966
|
SELLERS, THOMAS
|
H. LEE MOFFITT CANCER CTR & RES INST
|
|
A Novel Oncogenic Role for Cdc20 Implications in Adult T Cell Leukemia Treatment
|
5R00CA183914-05
|
$148,607
|
WAN, LIXIN
|
H. LEE MOFFITT CANCER CTR & RES INST
|
|
Optimal BET inhibitor combination therapies in triple negative breast cancer
|
1F30CA228208-01
|
$35,516
|
GE, YAWEI
|
HARVARD MEDICAL SCHOOL
|
|
Indiana University Melvin and Bren Simon Cancer Center Support Grant
|
3P30CA082709-19S1
|
$106,993
|
LOEHRER, PATRICK
|
INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
|
|
Indiana University Melvin and Bren Simon Cancer Center Support Grant
|
3P30CA082709-19S2
|
$250,000
|
LOEHRER, PATRICK
|
INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
|
|
Indiana University Melvin and Bren Simon Cancer Center Support Grant
|
5P30CA082709-19
|
$2,184,000
|
LOEHRER, PATRICK
|
INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
|
|
Impact of NF-kB methylation on chemoresistance and metastasis of breast cancer
|
1R03CA223906-01
|
$78,534
|
LU, TAO
|
INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
|
|
NOS1AP as a novel target for treating pathological pain
|
5R01CA200417-03
|
$282,800
|
HOHMANN, ANDREA
|
INDIANA UNIVERSITY BLOOMINGTON
|
Relevant funding data is only available when one cancer type or one research topic is selected.
|